Singapore markets closed
Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,610.70 +270.83 (+0.40%) CMC Crypto 200
1,423.33 -5.24 (-0.37%)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
NSE - NSE Real-time price. Currency in INR
Add to watchlist
At close: 03:30PM IST
| Previous close | 5,873.75 |
| Open | 5,899.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5,752.85 - 5,904.65 |
| 52-week range | 4,596.70 - 6,505.90 |
| Volume | |
| Avg. volume | 404,913 |
| Market cap | 964.505B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 17.30 |
| EPS (TTM) | 334.77 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 40.00 (0.69%) |
| Ex-dividend date | 15 Jul 2024 |
| 1y target est | 6,074.60 |
Business WireDr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
HYDERABAD, India, May 28, 2024--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Business WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, India & REYKJAVIK, Iceland, May 21, 2024--Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva®.
ZacksWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
© 2024 Yahoo. All rights reserved.